Sanofi/Regeneron's dupilumab has broad success in asthma
This article was originally published in Scrip
Partners Sanofi and Regeneron Pharmaceuticals are to move their anti-IL-4/IL-13 monoclonal antibody dupilumab into Phase III trials in moderate to severe uncontrolled asthma following positive results across its Phase IIb study population, which showed the drug had utility not just for the subset of patients with high eosinophils.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.